Abstract
Background:Janus kinase Inhibitors (JAKis) are approved for the treatment of Rheumatoid Arthritis (RA) in over 40 countries. The updated EULAR recommendations for RA treatment revised the preference of bDMARDs over...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have